---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-22-013773"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:40:27.788975+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Precigen Q2 loss from cont. ops $26.1M; divests Trans Ova Genetics for $170M

## Summary
- Loss from continuing ops $26.1M ($0.13 loss per share) vs $30.9M loss in Q2 2021.
- Total revenues down 24% YoY; SG&A decreased 15%.
- Agreed to sell Trans Ova Genetics to URUS for $170M cash upfront plus up to $10M earn-out; close expected Q3 2022.
- Cash and investments $132.8M as of June 30, 2022; proceeds intended to pay convertible notes due July 2023.
- Believes cash plus cost reductions provide runway into Q4 2023.

## SEC filing metadata
- accession: 0000950103-22-013773
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010322013773/0000950103-22-013773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010322013773/dp178450_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-22-013773
- JSON: https://secwatch.observer/filing/0000950103-22-013773.json
- Plain text: https://secwatch.observer/filing/0000950103-22-013773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.